Pediatric Oncology Collection
The AACR editors are proud to present this selection of impactful journal articles focusing on pediatric oncology, published from across the AACR journal portfolio.
The bromodomain BET inhibitor JQ1 suppresses tumor angiogenesis in models of childhood sarcoma.
Bid HK, Phelps DA, Xiao LA, Guttridge DC, Lin J, London C, et al. Molecular Cancer Therapeutics 2016; DOI:10.1158/1535–7163.MCT–15–05. [Published OnlineFirst February 23, 2016].
Preclinical evaluation of UAB30 in pediatric renal and hepatic malignancies.
Waters AM, Stewart JE, Atigadda VR, Mroczek-Musulman E, Muccio DD, Grubbs CJ, et al. Molecular Cancer Therapeutics 2016; DOI: 10.1158/1535–7163.MCT–15–0521. [Published OnlineFirst February 12, 2016].
Mastermind-like 3 controls proliferation and differentiation in neuroblastoma.
Heynen GJJE, Nevedomskaya E, Palit S, Basheer NJ, Lieftink C, Schlicker A, et al. Molecular Cancer Research 2016; DOI: 10.1158/1541–7786.MCR–15–0291–T. [Published OnlineFirst January 19, 2016].
Preclinical models provide scientific justification and translational relevance for moving novel therapeutics into clinical trials for pediatric cancer.
Langenau DM, Sweet-Cordero A, Wechsler-Reya RJ, Dyer MA. Cancer Research 2015;75:5176–86.
Confounding of the association between radiation exposure from CT scans and risk of leukemia and brain tumors by cancer susceptibility syndromes.
Meulepas JM, Ronckers CM, Merks J, Weijerman ME, Lubin JH, Hauptmann M. Cancer Epidemiology, Biomarkers & Prevention 2015;25:114–26.
The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma.
Infarinato NR, Park JH, Krytska K, Ryles HT, Sano R, Szigety KM, et al. Cancer Discovery 2016;6:96–107.
Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors.
Merchant MS, Wright M, Baird K, Wexler LH, Rodriguez-Galindo C, Bernstein D, et al. Clinical Cancer Research 2016;22:1364–70.
A heritable missense polymorphism in CDKN2A confers strong risk of childhood acute lymphoblastic leukemia and is preferentially selected during clonal evolution.
Walsh KM, de Smith AJ, Hansen HM, Smirnov IV, Gonseth S, Endicott AA, et al. Cancer Research 2015;75:4884–94.
Quality of physician communication about human papillomavirus vaccine: findings from a national survey.
Gilkey MB, Malo TL, Shah PD, Hall ME, Brewer NT. Cancer Epidemiology, Biomarkers & Prevention 2015;24:1673–9.
Sonic hedgehog signaling drives mitochondrial fragmentation by suppressing mitofusins in cerebellar granule neuron precursors and medulloblastoma.
Malhotra A, Dey A, Prasad N, Kenney AM. Molecular Cancer Research 2015;14:114–24.
Subsequent malignant neoplasms in a population-based cohort of pediatric cancer patients: a focus on the first 5 years.
Pole JD, Gu LY, Kirsh V, Greenberg ML, Nathan PC. Cancer Epidemiology, Biomarkers & Prevention 2015;24:1585–92.
A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma.
Mirabello L, Koster R, Moriarity RS, Spector LG, Meltzer PS, Gary J, et al. Cancer Discovery 2015;5:920–31.
Modulation of glucocorticoid resistance in pediatric T-cell acute lymphoblastic leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235.
Hall CP, Reynolds CP, Kang MH. Clinical Cancer Research 2016;22:621–32.